Articles tagged with Blood Cancer
Researchers analyzed 408 patients receiving immune checkpoint inhibitor therapy and found no increased risk of side effects from receiving both immunotherapy and the vaccine. The study supports NCCN's recommendations for COVID-19 vaccination in people with cancer, citing strong protection against severe COVID-19 for all variants.
Researchers at Universidad de Navarra identified a biomarker that predicts CAR T cell therapeutic capacity, which could improve treatment outcomes for patients. The study found that high CAR density in CAR T cells is associated with a worse clinical response in hematological tumors.
Researchers at the University of South Australia are using new technologies to speed up blood cancer diagnosis and treatment. The project aims to identify genetic variants that cause cancer, enabling clinicians to provide targeted treatments and improve patient management.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers are studying the interaction between obesity and nitric oxide synthase in triple-negative breast cancer, aiming to develop a new treatment strategy. Another team is investigating the role of NHE6 protein in multiple myeloma resistance to daratumumab treatment, with the goal of improving therapy outcomes for patients.
Researchers have discovered how a common blood stem cell mutation, DNMT3A R882, alters gene activity and produces abnormal blood cells that increase cancer risk. The study found that the mutant cells produce more red blood cells and platelets, leading to higher cardiovascular disease risks.
A new study of over half a million people with type 2 diabetes found that smoking and low physical activity significantly increase the risk of premature death. Individuals with type 2 diabetes who develop cancer are more likely to die in seven years if they are smokers or physically inactive.
A study of NASA astronauts found DNA mutations associated with spaceflight, increasing the risk of cardiovascular disease and blood cancer. Regular screening is recommended to monitor astronaut health.
A combination of immunotherapy and virotherapy using myxoma virus provides new hope for patients with treatment resistant cancers. The approach boosts the immune capacity to effectively target and destroy cancer cells, inducing a form of cell death called autosis.
A 3-dose Moderna COVID-19 vaccination schedule significantly improved SARS-CoV-2 antibody concentrations in immunocompromised patients. This improvement was comparable to those obtained by healthy individuals after the standard two-dose Moderna vaccination schedule.
A new scale called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale was found to be more effective at predicting frailty than conventional methods. The scale identifies high-risk medications linked to falls and fatigue, allowing oncology teams to deprescribe them and improve patients' overall health.
Researchers have constructed a comprehensive map of CLL genetic changes, providing a better understanding of the complex malignancy. The study identifies key genes and subtypes with distinct prognoses, paving the way for more accurate diagnoses and personalized treatments.
Researchers developed a method to produce generic CAR T cells from induced pluripotent stem cells (iPS cells), which could be produced at scale for multiple patients. The new cells showed enhanced anti-tumor activity and comparable efficacy to current clinical-grade cells.
A study found that a majority of online pharmacies selling imatinib, a chronic myeloid leukemia therapy, are uncertified and operate unsafely. Patients may face risks of nonadherence, treatment failures, and adverse events if they use these pharmacies.
Researchers used Guardant NGS to analyze nearly 17,000 lung cancer samples and found MET amplification in 1.2% of cases, with 20.8% having overlapping oncogenic drivers. The study suggests that high gene copy numbers and smaller amplified regions can be used to enrich for the true MET-sensitive population.
Researchers at Stanford University developed a custom molecule sBCMA-Fc V3 that inhibits the growth of both multiple myeloma and diffuse large B cell lymphoma in mice. The molecules were found to be nontoxic in monkeys, suggesting they could be used to treat humans with these deadly diseases.
A new study from Tel Aviv University found that CRISPR therapeutics can lead to a significant loss of genetic material in treated cells, potentially destabilizing the genome and promoting cancer. The researchers detected up to 10% of cells with lost chromosomes, highlighting the need for extra care when using this technology.
Researchers at Max Delbrück Center for Molecular Medicine found that silencing the EBAG9 gene in CAR T cells increases their effectiveness and reduces side effects. This breakthrough could lead to a new therapy approach for blood cancer patients.
A recent study published in CANCER found that adults with hematologic malignancies mounted immune responses after a COVID-19 booster dose, with 56% of nonresponders producing antibodies. However, the initial vaccine showed limited effectiveness, with only 48% of patients developing detectable antibodies.
Researchers have developed an app to help doctors identify patients with chronic lymphocytic leukemia (CLL) at risk of developing infections, allowing for earlier treatment. The app uses blood test results and genetic data to predict patient risk, improving treatment outcomes and reducing pressure on the healthcare system.
A novel liquid biopsy test can accurately detect cancer DNA in the blood of patients with metastatic breast cancer within five hours, potentially helping oncologists determine if treatments are working. The test's diagnostic accuracy is 85%, correctly detecting cancer 83% of the time and ruling out cancer 92% of the time.
A groundbreaking study using cellular barcoding in mice reveals that blood cells originate from two independent sources: hematopoietic stem cells and embryonic multipotent progenitor cells. These findings have significant implications for understanding blood cancers, bone marrow transplant, and the aging immune system.
Researchers identified a three-gene signature in multiple myeloma tumors that predicts a positive response to selinexor-based therapy. The discovery could improve patient selection for targeted agents and expand the use of the drug into patients who haven't failed other therapies.
A new study published in Blood Advances reveals significant disparities in end-of-life care for individuals with hematologic malignancies living in rural areas versus metropolitan regions. Rural residents are less likely to receive hospice care, instead often dying in nursing facilities or at home without palliative care.
Researchers have discovered a new treatment that combines CAR-T cell therapy with interleukin-7 to enhance its effectiveness in treating blood cancers. The treatment results in significantly increased anti-tumor activity, improved survival rates, and reduced tumor growth in mice.
A new study found that adult survivors of childhood cancer are 80% more likely to be undertreated for cardiovascular risk factors, including hypertension, diabetes, and high cholesterol. The study highlights the need for increased awareness among healthcare professionals and improved health management strategies for cancer survivors.
A new study found that patients with multiple myeloma who received a three-drug combination therapy had improved progression-free survival if they underwent an autologous stem cell transplant soon after treatment. The use of maintenance lenalidomide also conferred substantial clinical benefit.
Researchers discovered that leukemia-initiating cells in MLL-rearranged B-ALL can switch between two metabolic states, which makes them difficult to target. Targeting the quiet, stem cell-like state curbs the leukemia by forcing the cells back to an active proliferation state.
Researchers found that hypomethylating agents can activate the SALL4 oncogene in patients with myelodysplastic syndrome, resulting in poor survival outcomes. Early intervention targeting SALL4 pathways may improve treatment and patient outcomes.
A new study published in Blood Advances found that virtual frailty assessments are both safe and feasible when conducted virtually. The study evaluated 185 patients with blood cancers who completed a virtual assessment, finding that 81.1% successfully completed the test without falls or safety events.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A large-scale study has found that men with prostate cancer have a 50% higher risk of developing serious and potentially fatal blood clots during the five years after their diagnosis. This increased risk is significant because venous thromboembolism (VTE) is a leading cause of death among people with cancer.
A study found that patients with IgD multiple myeloma have a worse prognosis than other types, with higher mortality rates and more kidney damage. The rare blood cancer produces excessive light chains that can damage the kidneys if left untreated.
Researchers at USC have developed an innovative treatment for prostate cancer, known as synthetic immune receptor (SIR-T) therapy, which has shown promising results in preclinical studies. The new technology was adapted from CAR-T therapy and aims to revolutionize the treatment of not only prostate cancer but also other cancers.
New research suggests that PSA screening has remarkably favorable tradeoffs, particularly for Black men, who disproportionately bear the burden of prostate cancer mortality and morbidity. The study's findings support the use of PSA screening for high-risk groups, including Black men, and highlight the need to revise clinical guidelines...
A new lymphoma treatment, zanubrutinib, has been found to be effective in 80% of patients with marginal zone lymphoma, resulting in significant cancer shrinkage. However, its impact on follicular lymphoma is less pronounced.
Researchers have pinpointed a possible new target for treating patients with juvenile myelomonocytic leukemia (JMML), a highly aggressive blood cancer. Treatment using anti-inflammatories showed promise in rescuing JMML-like symptoms in zebrafish, suggesting a potential new approach to combating the disease.
A new sensor technology allows for real-time monitoring of lactate levels in the brain, providing insights into energy metabolism and potential applications in cancer detection. The sensors corrected for hemodynamic artifacts using MRI-informed corrections enable accurate cell-specific lactate level recordings.
A systematic review and meta-analysis of 81 studies found that COVID-19 patients with cancer had a higher risk of death compared to those without cancer. Younger age, lung, and hematologic cancers were identified as risk factors for poor outcomes from COVID-19
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
The study found significant heterogeneity among non-hematopoietic cells (NHCs) in human lymph nodes, with subgroups exhibiting distinct transcriptional changes and interaction patterns with malignant cells. This discovery may lead to the identification of potential biomarkers for therapeutic approaches.
A new study reveals a gene called KLF4 that normally suppresses tumor formation but is reprogrammed in acute promyelocytic leukemia, an aggressive type of blood cancer. Overexpressing KLF4 can suppress the growth of cancerous cells and reverse the effects of the disease.
A UCLA-led team has created a roadmap tracing each step in human blood stem cell development, providing a blueprint for producing fully functional blood stem cells. The map could help expand treatment options for blood cancers and inherited disorders.
Adding immunotherapy to chemotherapy before surgery reduced the risk of recurrence and death in lung cancer patients by 37%, according to a phase III trial. The treatment also led to a nearly twelvefold increase in pathological complete response, with 24% of patients achieving no active cancer remaining when the tumor was removed.
A study by University of Helsinki researchers found that the immune system attacks itself in rare type of blood cancer. The immune system plays a role in the development and growth of cancer cells, making current therapies less effective.
A third dose of COVID-19 vaccine significantly increases immune responses in patients with multiple myeloma, but a subset remains vulnerable. The study found that 88% of patients developed antibodies after the third dose, leading to improved neutralization of the wild-type virus.
A study using the nation's largest COVID-19 data resource found that the vaccine protects most cancer patients from getting COVID, but those with certain types of cancer have a higher risk of breakthrough infections. The research also highlights the importance of continued vaccination efforts to protect cancer patients.
Researchers discovered that a genetic mutation causing odd-shaped nuclei may lead to earlier diagnosis and treatment of certain leukemias. The study found that the loss of nuclear Lamin B1 induces defects in nuclear morphology and genome instability, setting the stage for cancer.
The American Association for Cancer Research (AACR) has announced the recipients of its 2022 Scientific Achievement Awards and Lectureships, recognizing Tony Hunter, Christina Curtis, John E. Dick, Kevan M. Shokat, and Lee M. Ellis for their groundbreaking contributions to cancer research.
Hokkaido University scientists have identified CDK6 as a promising target for treating adult T-cell leukemia/lymphoma (ATLL) with the drug palbociclib. The combination of palbociclib with everolimus also showed significant tumor growth reduction and minimal side effects in mice models.
Researchers at Okayama University have created a new method to kill cancer cells using light-activated protein AR3, reducing the risk of adverse reactions. The approach uses green light to trigger apoptosis in targeted cells, offering a promising alternative to conventional treatments.
A new study from Vanderbilt University Medical Center found that 10-second videos of white blood cell motion can predict blood cancer relapse in stem cell and bone marrow transplant patients. The study showed that patients with high adherence levels and rolling along vessel walls were more than three times as likely to have a relapse o...
Dr. John E. Dick will receive the inaugural AACR Award for Outstanding Achievement in Blood Cancer Research for his groundbreaking discoveries on leukemic stem cells and their mechanisms. His research has provided crucial insights into leukemia progression, survival rates, and treatment response.
Scientists have identified diagnostic features of circulating tumour DNA (ctDNA) in blood samples, which can predict treatment response and patient outcome in aggressive lymphoma. The study reveals significant heterogeneity among patients, with high ctDNA levels associated with poorer survival rates.
The ZUMA-12 trial shows axi-cel achieved a high rate of complete response in patients with high-risk large B-cell lymphoma, with an estimated overall survival rate of 91% at 12 months.
Researchers at Cincinnati Children's Hospital Medical Center have identified a protein crucial to AML cell survival and found a small molecule that blocks its function, killing cancer cells in lab dishes and mouse models. This potential breakthrough could lead to novel therapies for AML and other conditions.
A new study has found that World Trade Center responders have an increased mutational burden, elevating their risk for blood cancers and cardiovascular disease. The researchers compared DNA samples from 203 Nashville firefighters to a control group of 52 firefighters who were not exposed to particulate matter at the disaster.
A study published in Nature Medicine defines distinct subgroups of stem cells that expand during MDS treatment and drive resistance. Researchers found that targeting these specific stem cell classes with therapies like venetoclax may improve outcomes for patients with disease progression.
Researchers at UNC Lineberger Comprehensive Cancer Center have developed a new therapeutic approach using a small-molecule inhibitor of the chromatin-modulatory enzyme EZH2 to target aggressive cancer cells. The treatment also targets cMyc, a prominent cancer-causing factor, and shows profound tumor killing effects.
Researchers have identified a group of clinical signs that can be paired with genetic testing to better inform the timing of more aggressive treatment for leukemia patients. The study used a mouse model to understand how genetic mutations trigger bone marrow failure and life-threatening complications.